Fresenius/FRE

€26.56

0.49%
-
1D1W1MYTD1YMAX

About Fresenius

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Ticker

FRE

Sector

Healthcare

Trading on

XETRA

Industry

Healthcare Facilities

CEO

Employees

193,865

Headquarters

Bad homburg, Germany

Fresenius Metrics

BasicAdvanced
€14.99B
Market cap
-
P/E ratio
-€1.05
EPS
1.07
Beta
-
Dividend rate
€14.99B
1.07043
€31.22
€23.93
1.13M
1.342
1.072
69.735
83.32
36.127
5.75%
0.39%
1.79%
0.55%
0.672
0.789
10.869
5.478
2%
3.56%
-69.49%
-14.97%
-41.06%

What the Analysts think about Fresenius

Analyst Ratings

Majority rating from 21 analysts.
Buy

Price Targets

Average projection from 18 analysts.
32.83% upside
High €43.00
Low €28.00
€26.56
Current price
€35.28
Average price target

Fresenius Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10.81% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€5.68B
2.9%
Net income
€-614M
51.23%
Profit margin
-10.81%
47.07%

Fresenius Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 256.61%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
€0.61
€0.67
-€0.72
-€1.09
-
Expected
€0.59
€0.59
€0.62
€0.70
€0.70
Surprise
2.81%
13.33%
-215.29%
-256.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and Deutsche Börse. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Fresenius stock?

Fresenius (FRE) has a market cap of €14.99B as of April 17, 2024.

What is the P/E ratio for Fresenius stock?

The price to earnings (P/E) ratio for Fresenius (FRE) stock is 0 as of April 17, 2024.

Does Fresenius stock pay dividends?

No, Fresenius (FRE) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Fresenius dividend payment date?

Fresenius (FRE) stock does not pay dividends to its shareholders.

What is the beta indicator for Fresenius?

Fresenius (FRE) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Fresenius stock price target?

The target price for Fresenius (FRE) stock is €35.28, which is 32.83% above the current price of €26.56. This is an average based on projections from 18 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Fresenius stock

Buy or sell Fresenius stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing